Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1057171 | 0.89 | TSHR (0.43) | TSHRALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL11908924 | 0.83 | ALDH1A1 (0.33) | ALDH1A1HPGD | |
| SCHEMBL14144642 | 0.80 | ALDH1A1 (0.34) | ALDH1A1HSD17B10 | |
| SCHEMBL13837931 | 0.80 | HDAC3 (0.42) | TSHRALDH1A1MAPTLMNAHSD17B10 | |
| Carbon Monoxide SCHEMBL966181 | 0.80 | TSHR (0.34) | TSHRALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL28322692 | 0.79 | TSHR (0.42) | TSHRMIFALDH1A1MAPTLMNA | |
| SCHEMBL966033 | 0.78 | HSP90AB1 (0.41) | TSHRALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL22184138 | 0.77 | PSMB8 (0.35) | KMT2A | |
| SCHEMBL28992178 | 0.73 | NAAA (0.49) | TSHRALDH1A1LMNAHTTHPGD | |
| SCHEMBL28992213 | 0.73 | NAAA (0.49) | TSHRALDH1A1MAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322827-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | TSHR 1177/4885MIF 4738/4885ALDH1A1 767/4885 |
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | TSHR 1705/4885MIF 4820/4885ALDH1A1 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.